Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 252

1.

RAS Regulates the Transition from Naive to Primed Pluripotent Stem Cells.

Altshuler A, Verbuk M, Bhattacharya S, Abramovich I, Haklai R, Hanna JH, Kloog Y, Gottlieb E, Shalom-Feuerstein R.

Stem Cell Reports. 2018 Mar 13;10(3):1088-1101. doi: 10.1016/j.stemcr.2018.01.004. Epub 2018 Feb 15.

2.

Ras Signaling Inhibitors Attenuate Disease in Adjuvant-Induced Arthritis via Targeting Pathogenic Antigen-Specific Th17-Type Cells.

Zayoud M, Marcu-Malina V, Vax E, Jacob-Hirsch J, Elad-Sfadia G, Barshack I, Kloog Y, Goldstein I.

Front Immunol. 2017 Jul 7;8:799. doi: 10.3389/fimmu.2017.00799. eCollection 2017.

3.

Continuous treatment with FTS confers resistance to apoptosis and affects autophagy.

Schmukler E, Wolfson E, Elazar Z, Kloog Y, Pinkas-Kramarski R.

PLoS One. 2017 Feb 2;12(2):e0171351. doi: 10.1371/journal.pone.0171351. eCollection 2017.

4.

Viral oncomiR spreading between B and T cells is employed by Kaposi's sarcoma herpesvirus to induce non-cell-autonomous target gene regulation.

Rainy N, Zayoud M, Kloog Y, Rechavi O, Goldstein I.

Oncotarget. 2016 Jul 5;7(27):41870-41884. doi: 10.18632/oncotarget.9627.

5.

Intercellular transfer of small RNAs from astrocytes to lung tumor cells induces resistance to chemotherapy.

Menachem A, Makovski V, Bodner O, Pasmanik-Chor M, Stein R, Shomron N, Kloog Y.

Oncotarget. 2016 Mar 15;7(11):12489-504. doi: 10.18632/oncotarget.7273.

6.

Regulation of alternative splicing at the single-cell level.

Faigenbloom L, Rubinstein ND, Kloog Y, Mayrose I, Pupko T, Stein R.

Mol Syst Biol. 2015 Dec 28;11(12):845. doi: 10.15252/msb.20156278.

7.

The association between let-7, RAS and HIF-1α in Ewing Sarcoma tumor growth.

Hameiri-Grossman M, Porat-Klein A, Yaniv I, Ash S, Cohen IJ, Kodman Y, Haklai R, Elad-Sfadia G, Kloog Y, Chepurko E, Feinmesser M, Issakov J, Sher O, Luria D, Kollender Y, Weizman A, Avigad S.

Oncotarget. 2015 Oct 20;6(32):33834-48. doi: 10.18632/oncotarget.5616.

8.

Enhancing FTS (Salirasib) efficiency via combinatorial treatment.

Wolfson E, Schmukler E, Schokoroy ST, Kloog Y, Pinkas-Kramarski R.

Biol Cell. 2015 May;107(5):130-43. doi: 10.1111/boc.201400087. Epub 2015 Apr 21. Review.

PMID:
25735913
9.

Novel LIMK2 Inhibitor Blocks Panc-1 Tumor Growth in a mouse xenograft model.

Rak R, Haklai R, Elad-Tzfadia G, Wolfson HJ, Carmeli S, Kloog Y.

Oncoscience. 2014 Jan 1;1(1):39-48. eCollection 2014.

10.

Interplay Between HGF/SF-Met-Ras Signaling, Tumor Metabolism and Blood Flow as a Potential Target for Breast Cancer Therapy.

Natan S, Tsarfaty G, Horev J, Haklai R, Kloog Y, Tsarfaty I.

Oncoscience. 2013 Dec 11;1(1):30-38. eCollection 2014.

11.

Inhibition of malignant thyroid carcinoma cell proliferation by Ras and galectin-3 inhibitors.

Menachem A, Bodner O, Pastor J, Raz A, Kloog Y.

Cell Death Discov. 2015 Nov 2;1:15047. doi: 10.1038/cddiscovery.2015.47. eCollection 2015.

12.

Analysis of gene expression array in TSC2-deficient AML cells reveals IRF7 as a pivotal factor in the Rheb/mTOR pathway.

Makovski V, Jacob-Hirsch J, Gefen-Dor C, Shai B, Ehrlich M, Rechavi G, Kloog Y.

Cell Death Dis. 2014 Dec 4;5:e1557. doi: 10.1038/cddis.2014.502.

13.

Interfering with the interaction between ErbB1, nucleolin and Ras as a potential treatment for glioblastoma.

Goldshmit Y, Trangle SS, Kloog Y, Pinkas-Kramarski R.

Oncotarget. 2014 Sep 30;5(18):8602-13.

14.

Vitamin D and S-farnesylthiosalicylic acid have a synergistic effect on hepatic stellate cells proliferation.

Neeman R, Abramovitch S, Sharvit E, Elad-Sfadia G, Haklai R, Kloog Y, Reif S.

Dig Dis Sci. 2014 Oct;59(10):2462-9. doi: 10.1007/s10620-014-3207-2. Epub 2014 Jun 19.

PMID:
24942325
15.

Non-coding RNAs as the bridge between epigenetic mechanisms, lineages and domains of life.

Sela M, Kloog Y, Rechavi O.

J Physiol. 2014 Jun 1;592(11):2369-73. doi: 10.1113/jphysiol.2014.273045. Review.

16.

Targeting LIM kinase in cancer and neurofibromatosis.

Rak R, Kloog Y.

Cell Cycle. 2014;13(9):1360-1. doi: 10.4161/cc.28748. Epub 2014 Apr 3. No abstract available.

17.

Ras and autophagy in cancer development and therapy.

Schmukler E, Kloog Y, Pinkas-Kramarski R.

Oncotarget. 2014 Feb 15;5(3):577-86. Review.

18.

Metabolism addiction in pancreatic cancer.

Blum R, Kloog Y.

Cell Death Dis. 2014 Feb 20;5:e1065. doi: 10.1038/cddis.2014.38. Review.

19.

Cytotoxic-T-lymphocyte antigen 4 receptor signaling for lymphocyte adhesion is mediated by C3G and Rap1.

Kloog Y, Mor A.

Mol Cell Biol. 2014 Mar;34(6):978-88. doi: 10.1128/MCB.01024-13. Epub 2014 Jan 6.

20.

Chloroquine synergizes with FTS to enhance cell growth inhibition and cell death.

Schmukler E, Wolfson E, Haklai R, Elad-Sfadia G, Kloog Y, Pinkas-Kramarski R.

Oncotarget. 2014 Jan 15;5(1):173-84.

21.

Intercellular transfer of Ras: implications for immunity.

Goldstein I, Rainy N, Rechavi O, Kloog Y.

Cell Cycle. 2014;13(1):7-8. doi: 10.4161/cc.27020. Epub 2013 Nov 14. No abstract available.

22.

Therapeutic effect of farnesylthiosalicylic acid on adjuvant-induced arthritis through suppressed release of inflammatory cytokines.

Aizman E, Blacher E, Ben-Moshe O, Kogan T, Kloog Y, Mor A.

Clin Exp Immunol. 2014 Mar;175(3):458-67. doi: 10.1111/cei.12235.

23.

Disrupting the oncogenic synergism between nucleolin and Ras results in cell growth inhibition and cell death.

Schokoroy S, Juster D, Kloog Y, Pinkas-Kramarski R.

PLoS One. 2013 Sep 24;8(9):e75269. doi: 10.1371/journal.pone.0075269. eCollection 2013.

24.

Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemia.

Goldberg L, Tijssen MR, Birger Y, Hannah RL, Kinston SJ, Schütte J, Beck D, Knezevic K, Schiby G, Jacob-Hirsch J, Biran A, Kloog Y, Marcucci G, Bloomfield CD, Aplan PD, Pimanda JE, Göttgens B, Izraeli S.

Blood. 2013 Oct 10;122(15):2694-703. doi: 10.1182/blood-2013-01-477133. Epub 2013 Aug 23.

25.

H-Ras transfers from B to T cells via tunneling nanotubes.

Rainy N, Chetrit D, Rouger V, Vernitsky H, Rechavi O, Marguet D, Goldstein I, Ehrlich M, Kloog Y.

Cell Death Dis. 2013 Jul 18;4:e726. doi: 10.1038/cddis.2013.245.

26.

Fluid-flow induced wall shear stress and epithelial ovarian cancer peritoneal spreading.

Avraham-Chakim L, Elad D, Zaretsky U, Kloog Y, Jaffa A, Grisaru D.

PLoS One. 2013 Apr 10;8(4):e60965. doi: 10.1371/journal.pone.0060965. Print 2013.

28.
29.

Immunomodulatory properties of farnesoids: the new steroids?

Mor A, Aizman E, Chapman J, Kloog Y.

Curr Med Chem. 2013;20(10):1218-24. Review.

PMID:
23432580
30.

Rasosomes originate from the Golgi to dispense Ras signals.

Grunwald A, Gottfried I, Cox AD, Haklai R, Kloog Y, Ashery U.

Cell Death Dis. 2013 Feb 14;4:e496. doi: 10.1038/cddis.2013.16.

31.

Ras inhibition enhances autophagy, which partially protects cells from death.

Schmukler E, Grinboim E, Schokoroy S, Amir A, Wolfson E, Kloog Y, Pinkas-Kramarski R.

Oncotarget. 2013 Jan;4(1):145-55.

32.

Ras chaperones: new targets for cancer and immunotherapy.

Kloog Y, Elad-Sfadia G, Haklai R, Mor A.

Enzymes. 2013;33 Pt A:267-89. doi: 10.1016/B978-0-12-416749-0.00012-9. Epub 2013 Aug 8. Review.

PMID:
25033809
33.

Mechanisms of antiproliferative drug release from bioresorbable porous structures.

Kraitzer A, Alperstein D, Kloog Y, Zilberman M.

J Biomed Mater Res A. 2013 May;101(5):1302-10. doi: 10.1002/jbm.a.34436. Epub 2012 Oct 15.

PMID:
23065767
34.

Ras oncoproteins transfer from melanoma cells to T cells and modulate their effector functions.

Vernitsky H, Rechavi O, Rainy N, Besser MJ, Nagar M, Schachter J, Lerenthal Y, Ehrlich M, Kloog Y, Goldstein I.

J Immunol. 2012 Nov 1;189(9):4361-70. doi: 10.4049/jimmunol.1200019. Epub 2012 Oct 1.

35.

Computer-based identification of a novel LIMK1/2 inhibitor that synergizes with salirasib to destabilize the actin cytoskeleton.

Mashiach-Farkash E, Rak R, Elad-Sfadia G, Haklai R, Carmeli S, Kloog Y, Wolfson HJ.

Oncotarget. 2012 Jun;3(6):629-39.

36.

Celecoxib enhances the anti-inflammatory effects of farnesylthiosalicylic acid on T cells independent of prostaglandin E(2) production.

Mor A, Aizman E, Kloog Y.

Inflammation. 2012 Oct;35(5):1706-14. doi: 10.1007/s10753-012-9488-8.

PMID:
22688643
37.

FTS and 2-DG induce pancreatic cancer cell death and tumor shrinkage in mice.

Goldberg L, Israeli R, Kloog Y.

Cell Death Dis. 2012 Mar 15;3:e284. doi: 10.1038/cddis.2012.24.

38.
39.

Galectin-3 mediates cross-talk between K-Ras and Let-7c tumor suppressor microRNA.

Levy R, Biran A, Poirier F, Raz A, Kloog Y.

PLoS One. 2011;6(11):e27490. doi: 10.1371/journal.pone.0027490. Epub 2011 Nov 15.

40.

Prevention of induced colitis in mice by the ras antagonist farnesylthiosalicylic acid.

Oron T, Elad-Sfadia G, Haklai R, Aizman E, Brazowski E, Kloog Y, Reif S.

Dig Dis Sci. 2012 Feb;57(2):320-6. doi: 10.1007/s10620-011-1880-y. Epub 2011 Sep 8.

PMID:
21901261
41.

Ras inhibition induces insulin sensitivity and glucose uptake.

Mor A, Aizman E, George J, Kloog Y.

PLoS One. 2011;6(6):e21712. doi: 10.1371/journal.pone.0021712. Epub 2011 Jun 29.

42.

Inhibition of contact sensitivity by farnesylthiosalicylic acid-amide, a potential Rap1 inhibitor.

Mor A, Haklai R, Ben-Moshe O, Mekori YA, Kloog Y.

J Invest Dermatol. 2011 Oct;131(10):2040-8. doi: 10.1038/jid.2011.152. Epub 2011 Jun 30.

43.

Mechanophysical stimulations of mucin secretion in cultures of nasal epithelial cells.

Davidovich NE, Kloog Y, Wolf M, Elad D.

Biophys J. 2011 Jun 22;100(12):2855-64. doi: 10.1016/j.bpj.2011.04.040.

44.

Phenotypic reversion of invasive neurofibromin-deficient schwannoma by FTS: Ras inhibition reduces BMP4/Erk/Smad signaling.

Barkan B, Kloog Y, Ehrlich M.

Mol Cancer Ther. 2011 Aug;10(8):1317-26. doi: 10.1158/1535-7163.MCT-10-1087. Epub 2011 Jun 1.

45.

Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis.

Makovski V, Haklai R, Kloog Y.

Int J Cancer. 2012 Mar 15;130(6):1420-9. doi: 10.1002/ijc.26139. Epub 2011 Aug 1.

46.

The Ras antagonist, farnesylthiosalicylic acid (FTS), decreases fibrosis and improves muscle strength in dy/dy mouse model of muscular dystrophy.

Nevo Y, Aga-Mizrachi S, Elmakayes E, Yanay N, Ettinger K, Elbaz M, Brunschwig Z, Dadush O, Elad-Sfadia G, Haklai R, Kloog Y, Chapman J, Reif S.

PLoS One. 2011 Mar 22;6(3):e18049. doi: 10.1371/journal.pone.0018049.

47.

Oncogenic synergism between ErbB1, nucleolin, and mutant Ras.

Farin K, Schokoroy S, Haklai R, Cohen-Or I, Elad-Sfadia G, Reyes-Reyes ME, Bates PJ, Cox AD, Kloog Y, Pinkas-Kramarski R.

Cancer Res. 2011 Mar 15;71(6):2140-51. doi: 10.1158/0008-5472.CAN-10-2887. Epub 2011 Jan 21. Erratum in: Cancer Res. 2011 May 15;71(10):3732.

48.

Trans-SILAC: sorting out the non-cell-autonomous proteome.

Rechavi O, Kalman M, Fang Y, Vernitsky H, Jacob-Hirsch J, Foster LJ, Kloog Y, Goldstein I.

Nat Methods. 2010 Nov;7(11):923-7. doi: 10.1038/nmeth.1513. Epub 2010 Oct 10.

PMID:
20935649
49.

The combined treatment of Copaxone and Salirasib attenuates experimental autoimmune encephalomyelitis (EAE) in mice.

Aizman E, Mor A, Chapman J, Assaf Y, Kloog Y.

J Neuroimmunol. 2010 Dec 15;229(1-2):192-203. doi: 10.1016/j.jneuroim.2010.08.022. Epub 2010 Sep 24.

PMID:
20869125
50.

Inhibitory effect of farnesylthiosalicylic acid on mediators release by mast cells: preferential inhibition of prostaglandin D(2) and tumor necrosis factor-α release.

Mor A, Ben-Moshe O, Mekori YA, Kloog Y.

Inflammation. 2011 Oct;34(5):314-8. doi: 10.1007/s10753-010-9236-x.

PMID:
20706780

Supplemental Content

Support Center